The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies frequently characterized by a mutation in JAK2 (JAK2V617F). Peripheral blood (PB) CD34
Introduction
The Philadelphia chromosome negative myeloproliferative neoplasms (Ph À MPNs), which include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are thought to result from the transformation of a multipotent hematopoietic stem cell.
1,2 These Ph À MPNs are characterized by trilineage bone marrow (BM) proliferation resulting in increased production of red cells, granulocytes and platelets, which largely determines the clinical manifestations of the MPNs. 1, 2 Chromosomal abnormalities occur in 25-29% of patients with PV, approximately 50% of patients with PMF; whereas in ET, cytogenetic abnormalities are found infrequently (B8%). 1, 3, 4 The spectrum of cytogenetic aberrations in Ph À MPNs ranges from numerical gains and losses to structural changes including unbalanced translocations. 1, 3, 4 The most common chromosomal abnormalities in Ph À MPNs are þ 9/ þ 9p, del(20q), del(13q), þ 8 and partial duplication of 1q. 1, 3, 4 A somatic activating mutation of the JAK2 tyrosine kinase (JAK2V617F) has been identified in the hematopoietic cells of over 90% of the patients with PV, and 50% of the patients with ET and PMF. [5] [6] [7] [8] [9] Subsequently, another mutation in the thrombopoietin receptor (MplW515L/K) has been documented in about 5% of the patients with PMF and ET. 10, 11 The currently available data clearly show that these mutations play pivotal roles in the development of the clinical manifestations of the Ph À MPNs. [5] [6] [7] [8] [9] [10] In a mouse marrow transplant model, BM cells transduced with JAK2V617F lead to a clinical phenotype that closely resembles PV including erythrocytosis, extramedullary hematopoiesis and marrow fibrosis. [12] [13] [14] [15] Recently, several groups have reported that transgenic expression of JAK2V617F in mice recapitulates many aspects of the clinical phenotype of ET, PV and PMF. [16] [17] [18] The Ph À MPNs are clonal hematopoietic stem cell diseases likely involving both myeloid and lymphoid lineages. 1, [19] [20] [21] [22] [23] [24] [25] [26] Using X-chromosome-linked polymorphisms, several investigators have shown a monoclonal pattern involving multiple myeloid lineages (granulocytes, erythrocytes, platelets, monocytes) in patients with PV, ET and PMF. 19, 20 Using similar cell clonality assays, some investigators have reported that B- 21 and/ or T-lymphocytes 22, 23 can also be involved by the malignant process in a sub-population of patients with PV, ET and PMF. Studies of Ras mutations and fluorescence in situ hybridization (FISH) analyses have also suggested monoclonality of T-lymphocytes in some PMF patients. 24, 25 In addition, Kralovics et al. 26 have shown that using 9p, 10q and 11q LOH as clonality markers, a minor proportion of T cells may be generated from the malignant clone in occasional patients with PV. Furthermore, studies of c-kit mutations have shown monoclonality of mast cells (MCs), neutrophils, basophils, eosinophils, monocytes and B cells in patients with systemic mastocytosis, which is also belonging to the Ph À MPNs. 27 The JAK2V617F mutation is present in the CD34 þ cells as well as cells belonging to several myeloid lineages (granulocytes, erythrocytes and monocytes) in the majority of patients with PV and the lymphoid cells of a sub-population of PV patients. [28] [29] [30] [31] Hu et al. 32 and Chaligné et al. 33 have reported that the MplW515L/K mutations are present in granulocytes, monocytes, platelets, natural killer cells as well as B-and Tlymphocytes in patients with PMF, indicating that the MplW515L/K mutations originate in a progenitor cell common to both myeloid and lymphoid cells. 32, 33 Despite being one of the myeloid lineages, the involvement of MCs by the malignant process in PV, ET and PMF has not been reported earlier.
In this study, we report that peripheral blood (PB) CD34 þ cells from patients with PV and PMF generated significantly smaller numbers of MCs in vitro as compared with granulocytecolony-stimulating factor mobilized (Gmob) or normal PB CD34 þ cells, which might be due to an increased rate of apoptosis by the cultured MPN MCs. Although there were similar numbers of assayable MC progenitors within the PB CD34 þ cells isolated from Gmob/normal individuals and MPN patients, MPN PB CD34 þ cells formed MC colonies composed of smaller numbers of MCs as compared with Gmob/normal CD34 þ cells. A higher percentage of the cultured MPN MCs expressed FceRIa, CD63 and CD69 as compared with Gmob/ normal MCs. By using JAK2V617F, MplW515L and chromosomal abnormalities as clonality markers, MCs were shown to be involved by the malignant process in patients with PV and PMF. Furthermore, erlotinib, a JAK2V617F inhibitor, was shown to be capable of inhibiting the abnormal MPN MC progenitor cells in vitro, indicating that malignant MC progenitor cells are a possible cellular target of small molecule inhibitors of JAK2.
Materials and methods

Patients and normal donor
All human tissue samples were obtained after informed consent was provided according to guidelines of the Institutional Review Board of the Mount Sinai School of Medicine, NY. All patients met the revised WHO diagnostic criteria for PV or PMF.
1,34 PV patients were treated with phlebotomy and low-dose aspirin, whereas PMF patients were receiving solely supportive care at the time of study. Granulocytes and CD34 þ cells were isolated from 30 to 50 ml of PB from PMF patients or 400 ml discarded therapeutic phlebotomy units from PV patients as described earlier. 28 Gmob or normal PB CD34 þ cells were purchased from StemCell Technologies Inc. (Vancouver, Canada).
Purification of human CD34
þ cells
Peripheral blood samples were layered onto Ficoll-Hypaque (1.077 g/ml), and low-density mononuclear cells were separated by centrifugation. CD34 þ cells were isolated from the mononuclear cells using an Easy Sep Human CD34 Selection Kit (StemCell Technologies Inc.) according to the manufacturer's instructions. As PV and PMF patients constitutively mobilize CD34 þ cells into the PB to moderate and high degrees, respectively, 35 we were able to isolate 2-8 Â 10 6 CD34 þ cells from a single PV phlebotomy unit and 1-8 Â 10 6 CD34 þ cells from 30 to 50 ml of blood from PMF patients. CD34
þ cells, with a purity of 90% or greater, were used for subsequent experiments.
Human cultured MCs (HCMCs)
Human cultured MCs were generated in vitro by minor modifications of the methods described earlier by Toru et al. 36 Briefly, CD34 þ cells were suspended in tissue culture flasks in a-MEM supplemented with 20% fetal bovine serum in the presence of human stem cell factor (SCF) (100 ng/ml) and human interleukin (IL)-6 (50 ng/ml) for 7-8 weeks. Half of the media was replaced weekly. Adherent cells including macrophages were eliminated by transferring non-adherent cells to fresh culture flasks.
Immunocytochemical assays
Human cultured MCs were spun onto glass slides by cytocentrifugation. The slide preparations were stained with WrightGiemsa and Alcian blue as described earlier. 36 For anti-tryptase and anti-chymase immunocytochemical staining, slides were fixed with Carnoy's solution (Ricca Chemical, Arlington, TX, USA) over night at 4 1C. After washing with Tris-buffered saline, the slides were blocked with rabbit serum for 10 min followed by incubation at room temperature for 1 h with a mouse antihuman tryptase or a mouse anti-human chymase monoclonal antibody (mAb; Chemicon International, Temecula, CA, USA) and then washed with Tris-buffered saline. Using an Immunophosphatase Secondary Detection System (Chemicon International), the samples were incubated at room temperature for 10 min with a secondary Ab conjugated with biotin. After washing, the samples were further incubated at room temperature for 10 min with soluble complexes of streptavidin-alkaline phosphatase. Finally, these slides were developed with the addition of a chromogenic substrate. HCMCs with a purity of 95% or greater as determined by morphological examination of Wright-Giemsa and Alcian blue-stained specimens were used for subsequent experiments. The small percentage of other cells (o5%) in the HCMC cultures were primarily monocytes/ macrophages.
Flow cytometric analysis
The HCMCs were analyzed for MC surface markers using a flow cytometric analysis with a panel of mAbs against FceRIa, CD117, CD63 or CD69. HCMCs were suspended in phosphatebuffered saline containing 0.1% bovine serum albumin and incubated in 20% rabbit serum and 20% human serum for 30 min at 4 1C. The cells were then incubated with phycoerythrin conjugated anti-CD117 mAbs in combination with fluorescein-5-isothiocyanate conjugated anti-FceRIa, anti-CD63 or anti-CD69 mAbs (Becton Dickinson, San Jose, CA, USA) for 30 min at 4 1C. A separate cell aliquot was stained with isotype-matched mAbs labeled with the same fluorochromes. After washing, 2 mg/ml propidium iodide was added. The samples were then analyzed using a FACSCanto (Becton Dickinson, Mountain View, CA, USA). Routinely, 30 000 events were acquired per sample.
MC colony assays
The frequency of MC progenitor cells in the CD34 þ cells were assessed using Methocult (H4236; StemCell Technologies) according to a protocol described earlier. 37 One ml of 1.2% methylcellulose-based culture medium containing 1 Â 10 3 CD34 þ cells was plated into 35-mm non-tissue culture dishes in the presence of SCF (100 ng/ml), IL-6 (50 ng/ml) and IL-3 (5 ng/ml), and incubated at 37 1C with 5% CO 2 . All the cytokines used were a gift of Amgen (Thousand Oaks, CA, USA). On day 14 of incubation, 0.3 ml of the methylcellulose-based culture medium containing SCF (200 ng/ml) and IL-6 (100 ng/ml) was layered into each culture plate. On day 28, 1 ml of culture medium containing 2-mercaptoethanol, insulin-transferrin-selenium solution, SCF (200 ng/ml) and IL-6 (100 ng/ml) was added to each plate. All cultures were performed in triplicate and the number of colonies was enumerated after 35-42 days of culture. After 35 days of culture, the majority of the colonies (490% colonies) were MC colonies, whereas a small percentage of the colonies were macrophage and macrophages/ MC-mixed colonies. To examine the effect of erlotinib on MC colony formation, erlotinib (0, 2, 10 mM) was added to the culture medium at the initiation of the cultures.
Fluorescence in situ hybridization
Briefly, HCMCs were dropped into 10 ml of hypotonic solution (0.075 kmol KCl) on positively charged slides and allowed to air dry. The cells were fixed with Carnoy's fixative for 5 min at 4 1C and then dehydrated. The cells and probes (D8Z1 at 8p11-q11, P15 at 9p21, a-satellite DNA for the centromeric area of chromosome 9 and MLL at 11q23 were obtained from Vysis/Abbott Molecular, DePlaines, IL, USA) were co-denatured at 73 1C for 3 min and co-hybridized at 37 1C over night. The slides were washed with 0.4 Â standard saline citrate at 73 1C for 1.5 min and 0.1% NP-40 in 2 Â standard saline citrate at room temperature for 1 min. The slides were allowed to air dry and counterstained with DAPI (4,6-diamidino-2-phenylindole). Analysis and imaging of the MCs were performed with the Cytovysion 3.92 system (Applied Imaging, San Jose, CA, USA) and Zeiss Axioplan Microscope (Thornwood, NY, USA), and the percentage of cells exhibiting an abnormal nuclear signal pattern was determined.
JAK2V617F and MplW515L mutational analysis
The presence of JAK2V617F and MplW515L mutations in HCMCs and granulocytes were examined using PCR/direct sequencing as described earlier. 28, 32 Sequencing of the granulocytic genomic DNA showed that among the 22 PV and 15 PMF patients studied, 21 PV and 9 PMF patients were JAK2V617F positive, whereas 2 PMF patients had the MplW515L mutation.
The genotyping of individual MC colonies for JAK2V617F or wild-type JAK2 (JAK2WT) was performed by nested allelespecific PCR as we described earlier. 38, 39 The percentage of JAK2 V617F /JAK2 total allele in the genomic DNA of granulocytes from each patient was determined by realtime quantitative PCR using the allelic discrimination method as we described earlier. 28 Patients with a JAK2 V617F /JAK2 total allele ratio of 50% or greater were classified as high burden JAK2V617F, whereas JAK2V617F-positive patients with a JAK2 V617F /JAK2 total allele ratio of less than 50% were classified as low burden JAK2V617F.
MC capture by laser capture microdissection
Bone marrow cells from two MPN patients were spun onto slides (5000 cells/slide) by centrifugation. The slides were stained with Alcian blue and the percentages of Alcian blue positive MCs within the marrow nucleated cells were evaluated under a microscope. Eight to 10 Alcian blue positive MCs/ samples were captured by laser capture microdissection (LCM) from the slide preparations using the ArcturusXT system (Arcturus, MDS Analytical Technologies, Mountain View, CA, USA). The JAK2V617F mutation was analyzed by nested allele-specific PCR as described above.
Growth factor deprivation and apoptosis assay
Human cultured MCs (1 Â 10 5 /ml) were washed with phosphate-buffered saline and incubated over night in Iscove's modified Dulbecco's medium. MC apoptosis was analyzed both in the presence of cytokines and upon cytokine deprivation using an apoptosis detection kit (DeadEnd Fluorometric TUNEL System; Promega, Madison, WI, USA). The method is based on the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) technique and can detect apoptosis at very early stages. Briefly, HCMCs were cytocentrifuged onto slides and permeabilized with Triton X-100. The fragmented DNA of apoptotic cells was labeled with fluorescein-12-dUTP and the whole cell population was stained with DAPI. The localized green fluorescence of apoptotic cells (fluorescein-12-dUTP) in a blue background (DAPI) was detected by fluorescence microscopy and the percentage of apoptotic cells was determined by counting at least 200 cells on each of three duplicate slides.
Statistical analysis
The data were obtained by examining 22 patients with PV, 15 patients with PMF and 7 Gmob volunteers and 3 normal volunteers not receiving granulocyte-colony-stimulating factor. The results are expressed as the mean ± s.d. of data obtained from a varying number of individual experiments. Differences between percentages of apoptotic cells or cells expressing a particular marker were calculated using the Wilcoxon test, whereas differences between other variables were compared using a Student's t-test and/or analysis of variance. Statistical significance was assumed for Pp0.05.
Results
Morphological characterization of MCs cultured from PB CD34
Peripheral blood CD34 þ cells from 18 PV, 11 PMF, 7 Gmob volunteers and 3 normal donors were cultured in the presence of SCF (100 ng/ml) and IL-6 (50 ng/ml) for 7-8 weeks as described by Toru et al. 36 After 49 days, the cells harvested from each culture were phenotyped using Wright-Giemsa and Alcian blue staining, as well as anti-tryptase and anti-chymase immunocytochemical staining. Wright-Giemsa staining revealed a uniform phenotype of round basophilic cells containing many granules ( Figure 1A , a-c). The granules in these cells possessed the characteristic staining pattern of MCs when stained with Alcian blue ( Figure 1A, d-f ). Immunocytochemical staining revealed that the MCs generated from each culture contained 85-95% tryptase-positive cells and 60-80% chymase-positive cells ( Figure 1A , g-l), indicating that most of the cells were connective tissue-type MCs. These MCs (495% purity) were subsequently used for the experiments involving FISH, genomic DNA extraction and apoptosis.
We then examined the expression of CD117, FceRIa, CD63 and CD69 on the HCMCs generated from 5 Gmob/normal donors and 6 MPN patients using flow cytometry. CD117 was expressed on the majority of the HCMCs from both the Gmob/ normal (73.6±9.7%) and MPN (81.7±10.6%; P40.05, data not shown) CD34 þ cells. Approximately 1.4 ± 0.7% of Gmob/ normal HCMCs expressed FceRIa as compared with 29.4 ± 8.9% of MPN HCMCs (Po0.05; Figure 1B ). CD63 was expressed by 1.6±0.5% of Gmob/normal HCMCs as compared with 15.9 ± 6.4% of MPN HCMCs (Po0.05; Figure 1B) ; whereas 0.3±0.2% of Gmob/normal HCMCs expressed CD69 as compared with 11.6 ± 6.2% of MPN HCMCs (Po0.05; Figure 1B ). The increased expression of FceRIa, CD63 and CD69 on the MPN HCMCs is indicative of the increased activation status of the cultured MPN MCs.
Number of MCs generated from PV, PMF and normal PB CD34 þ cells
The total number of MCs generated from 1 Â 10 6 CD34 þ cells was enumerated after 49-56 days of culture. As shown in Figure 1C , Gmob/normal PB CD34 þ cells generated significantly greater numbers of MCs (range: 5.6-20. Colonies (4-10 colonies/sample) were randomly plucked and stained with Wright-Giemsa and Alcian blue to confirm that the cells within each colony were MCs (Figure 2A, a-c) Figure 3a) ; whereas B50% of PV511 MCs contained trisomy 9 (23/47).
We then examined if the JAK2V617F and/or MplW515L mutations were present in MPN HCMCs. Genomic DNA was extracted from HCMCs of 9 PV (all JAK2V617F þ ) and 6 PMF patients (3 JAK2V617F þ , 2 MplW515L þ /JAK2V617F À and 1 JAK2V617F À /MplW515L À ). PCR/direct sequencing revealed that the JAK2V617F mutation was present in HCMCs of each of the 12 JAK2V617F þ MPN patients; and the degree of allele chimerism of the JAK2V617F mutation in HCMCs was similar to that observed in the granulocytes (Figure 3b ). The JAK2V617F mutation was not detected in the HCMCs from the three JAK2V617F À PMF patients. PCR/direct sequencing also revealed that the MplW515L mutation was present in the HCMCs from the two MplW515L þ PMF patients, but not two MplW515L À PMF patients; the degree of MplW515L mutation chimerism was also similar to that observed in the granulocytes in each of the two PMF patients (Figure 3c ). We next analyzed the presence of JAK2V617F mutation in individual MC colonies derived from CD34 þ cells of 12 PV, 7 PMF and 2 Gmob volunteers. The genotyping of 15 MC colonies generated by PV503 CD34 þ cells are shown in Figure 3d , 4 colonies contained only JAK2WT allele, 3 contained both JAK2V617F and JAK2WT alleles and 8 contained only JAK2V617F allele. As shown in Table 1, JAK2V617F þ MC colonies were assayable from each of the 17 JAK2V617F þ MPN patients. JAK2WT MC colonies were present in each of the MPN patients except PV3. JAK2V617F homozygous MC colonies were present in each of the JAK2V617F þ MPN patient except PMF3 and PMF106; whereas JAK2V617F heterozygous MC colonies were detected in 13 out of the 17 JAK2V617F þ MPN patients.
The presence of the JAK2V617F mutation was also examined in the Alcian blue positive MCs (B10 cells), which were captured from BM aspirate slides from two MPN patients using LCM. The percentages of Alcian blue positive MCs within the BM nucleated cells were B0.2 and 0.3%, respectively, in the two MPN patients. The appearance of the BM cells from a MPN patient containing a typical Alcian blue positive MC and the image of the same area after the MC was captured is shown in Supplementary Figure 1A and B. When the JAK2V617F mutational status was analyzed using nested allele-specific PCR, the MCs captured from one MPN patient contained only JAK2V617F allele, whereas the BM MCs captured from the slides of the other MPN patient contained both JAK2V617F and JAK2WT alleles (see Supplementary Figure 1C ).
Increased apoptosis of cultured PV and PMF MCs
We then assessed the rate of apoptosis of the HCMCs from 10 PV, 7 PMF and 6 Gmob/normal volunteers both in the presence and absence of cytokines. HCMCs were cytocentrifuged onto slides and the degree of apoptosis was analyzed using DeadEnd Fluorometric TUNEL System. The localization of green fluorescent apoptotic cells in a blue background (DAPI) was detected using fluorescence microscopy ( Figure 4A, a-c) . In the presence of cytokines, the percentage of apoptotic MPN MCs (6.2 ± 2.3%) was significantly higher than that observed with Gmob/normal MCs (1.8 ± 1.1%; Po0.05; Figure 4B ). Upon cytokine deprivation, the percentage of apoptotic cells increased in the HCMCs from both sources. Again, a significantly higher percentage of apoptotic cells was observed in MPN HCMCs (15.8±4.2%) than Gmob HCMCs (3.4 ± 1.5%, Po0.01, Figure 4B ). These data indicate that MPN HCMCs are characterized by an increased rate of apoptosis. Abbreviations: Gmob, granulocyte-colony-stimulating factor mobilized volunteers; PB, peripheral blood; PMF, primary myelofibrosis; PV, polycythemia vera; WT, wild type.
JAK2V617F is present in MPN mast cells J Wang et al
Correlation of the number of HCMCs and MC colonies generated from CD34 þ cells as well as the percentage of apoptotic MCs with the JAK2V617F allele burden
We next correlated the number of MCs generated from CD34 þ cells, the number of MC colonies formed by CD34 þ cells and the percentage of apoptotic MCs occurring following cytokine deprivation with the granulocyte JAK2V617F allele burden of each MPN patient. As shown in Figure 5 , CD34 þ cells from JAK2WT MPN patients generated significant greater numbers of MCs than that of JAK2V617F þ MPN patients (Po0.05); whereas CD34 þ cells from low burden JAK2V617F MPN patients formed significant fewer MC colonies than JAK2WT or JAK2V617F high burden MPN patients (Po0.05). The percentage of apoptotic MCs generated from JAK2V617F high burden, low burden or JAK2WT MPN patients upon cytokine deprivation was similar (P40.05; Figure 5c ).
Effect of erlotinib on MC colony formation by PV or Gmob CD34
We have recently reported that erlotinib is a potent JAK2 inhibitor. 38 We, therefore, examined the effect of erlotinib on MC colony formation by MPN or Gmob CD34 þ cells. PB
were cultured in semisolid media in the presence of SCF þ IL-6 with or without the addition of erlotinib (0, 2 mM or 10 mM). The number of MC colonies formed by PV CD34 þ cells was significantly decreased when 2 mM erlotinib was added (Po0.05); while the addition of erlotinib (2 mM) had a modest effect on the number of MC colonies formed by Gmob CD34 þ cells (P40.05) (Figure 6a ). Furthermore, the percentage of JAK2V617F þ colonies assayed from MPN CD34 þ cells was reduced in the presence of erlotinib (2 or 10 mM), while the proportion of the JAK2WT colonies increased (Figure 6b ). In addition, the size of the MC colonies formed in the absence of erlotinib was larger than that formed in the presence of erlotinib (data not shown). These data thus show that JAK2V617F þ MC progenitor cells were more sensitive to erlotinib than JAK2WT MC progenitor cells, providing evidence that erlotinib selectively inhibits MPN MC growth.
Discussion
The Ph À MPNs are clonal hematopoietic stem cell diseases likely involving both myeloid and lymphoid lineages. 1, [19] [20] [21] [22] [23] [24] [25] [26] Using cell clonality assays including X-chromosome-linked polymorphisms, FISH and specific mutations (Ras, JAK2V617F and MplW515L), several myeloid lineages (granulocytes, erythrocytes, platelets and monocytes) have been shown to be involved by the malignant process in the majority of patients with PV, PMF and ET; and the lymphoid cells in a subpopulation of these patients. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Although MCs originate from the same progenitor cells, as granulocytes, erythrocytes, platelets and monocytes, whether MCs are also involved by the malignant process in PV, PMF and ET has not been previously explored. In this study, we established MC cultures from CD34 þ cells purified from PB of patients with PV and PMF, and examined the presence of JAK2V617F and/or MplW515L mutations as well as chromosomal abnormalities in the HCMCs. We have shown that the JAK2V617F mutation exist in both cultured MPN HCMCs and MC colonies derived from CD34 þ cells of JAK2V617F-positive MPN patients, but not in the normal control MCs. In addition, the MplW515L mutation was present in cultured MCs from two MplW515L þ PMF patients. A marker chromosome was also documented to be present in HCMCs from three MPN patients with chromosomal abnormalities by FISH. Our study thus provides the first evidence, which indicates that MCs are involved by the malignant process in PV and PMF.
Polycythemia vera is characterized by excessive proliferation of cells belonging to the erythroid lineage, whereas PMF is characterized by a profound hyperplasia of morphologically abnormal megakaryocytes. 1 Erythroid, megakaryocytic and MC lineages are ancestrally related with their development and differentiation largely controlled by a same transcription factor, GATA-1.
40 Therefore, the proliferation and differentiation of MC lineage could also be abnormal in patients with PV or PMF. In this study, we showed that PV and PMF PB CD34 þ cells gave rise to significantly fewer MCs than Gmob/normal PB CD34 þ cells in vitro. This phenomenon is associated with a significantly higher percentage of apoptotic HCMCs generated from PV and PMF CD34
þ cells as compared with HCMCs generated from Gmob/normal CD34 þ cells. In addition, cultured MPN MCs expressed increased levels of FceRIa, CD63 and CD69 as compared with Gmob/normal MCs. FceRI, the high-affinity receptor for IgE, is expressed on the surface of MCs and JAK2V617F is present in MPN mast cells J Wang et al basophils. 41 The clustering of the FceRI receptor, either through crosslinking of bound monomeric IgE by multivalent antigens or by antibodies directed against the FceRI receptor, triggers degranulation, which can be evaluated by measuring the release of histamine or proteases.
42 CD63 antigen is located on the granule membranes in MCs and basophils, activation of MCs or basophils induces fusion of cytoplasmic granules with the plasma membrane resulting in the expression of CD63 antigen on the cell surface as well as the successive release of mediators such as histamine. 43, 44 CD69 is a type II receptor belonging to the C-type lectin family of surface receptors, which was first described as an early activation antigen on lymphocytes. 45 CD63 and CD69 have been shown to be overexpressed in MCs from patients with indolent systemic MC disease. 45, 46 The higher percentage of FceRIa, CD63 and CD69 expressing HCMCs in the MPN cultures suggest that there is an increased activation in the MPN HCMCs, which might subsequently lead to the increased rate of apoptotic HCMCs.
Scott et al. 47 have reported that JAK2V617F homozygous erythroid colonies are the characteristics of a PV phenotype. By analyzing 177 MC colonies from 17 JAK2V617F þ patients with PV or PMF, JAK2V617F homozygous MC colonies were detected in 15 of the 17 JAK2V617F þ MPN patients; while JAK2WT MC colonies were present in 16 of the 17 patients. These results indicate that both JAK2WT and JAK2V617F homozygous MC progenitor cells were present in the overwhelming majority of the JAK2V617F þ PV or PMF patients. The presence of JAK2V617F homozygous progenitor cells common for both MC and erythroid cells appear to be a feature of JAK2V617F þ PV and PMF. Mast cells arise from multipotent hematopoietic progenitor cells in BM. 48, 49 MCs normally do not mature before leaving the ) isolated from patients with polycythemia vera (PV) (n ¼ 6) or granulocyte-colony-stimulating factor mobilized volunteers (Gmob) (n ¼ 4) were cultured in semisolid media in the presence or absence of erlotinib (0, 2, 10 mM) with stem cell factor þ interleukin-6. (a) Each column represents the mean ± s.d. of the number of MC colonies formed in the presence of erlotinib/the number of MC colonies formed without erlotinib Â 100. The number of MC colonies formed by PV CD34 þ cells in the presence of erlotinib (2 mM) was significantly lower than that assayed without inhibitor (Po0.05). (b) A JAK2V617F genotyping assay of MC colonies derived from PV CD34 þ cells with or without erlotinib (0, 2, 10 mM). Each column represents the mean±s.d. of the number of MC colonies formed in the presence of erlotinib/the number of MC colonies formed without erlotinib Â 100 (JAK2V617F homozygote: black column, heterozygote: gray, and JAK2WT, white). Differences between the numbers of MC colonies generated in the presence and absence of erlotinib were compared using a Student's t-test and analysis of variance.
JAK2V617F is present in MPN mast cells J Wang et al BM but circulate through the vascular system as immature progenitors that can then complete their development peripherally within connective or mucosal tissues. Kambe et al. 50 have shown that the complete differentiation of MC progenitor cells into mature MCs takes place only after they have migrated to peripheral tissues, using an in vivo model for human MC development. It is anticipated that mature MCs in the skin (dermal MCs), MC progenitor cells in the BM and HCMCs generated from PB CD34 þ cells in vitro should be of the same origin and share the same mutational status. To confirm that MCs are part of the JAK2V617F mutated clone in vivo, MCs (B10 cells) were captured from Alcian blue-stained cytospin preparations of BM aspirates from two MPN patients using LCM, and analyzed for JAK2V617F using nested allele-specific PCR (see Supplementary Figure) . In both instance, the MCs captured from the marrow slides were JAK2V617F positive (one sample was JAK2V617F homozygous and the other sample was JAK2V617F heterozygous, see Supplementary Figure) , indicating that MCs are also involved by the JAK2V617F mutation in vivo. The possible contamination of non-MC fragments with the captured MCs would not affect the results, as one of the samples was homozygous for JAK2V617F allele.
JAK2V617F occurs in the majority of the patients with PV, PMF and ET. The number of MCs generated by JAK2WT MPN CD34 þ cells was significantly greater than that by CD34 þ cells from JAK2V617F-positive MPN patients. In addition, CD34 þ cells from JAK2WT or JAK2V617F high burden MPN patients contained significantly greater numbers of MC progenitors than JAK2V617F low burden MPN patients. These data suggest that JAK2V617F mutation as well as its allele burden might play a role on the proliferation and differentiation of MPN MC progenitor cells. Lu et al. 51 have recently shown that JAK2V617F requires binding to a dimerized cytokine receptor for its activation. These receptors, such as erythropoietin receptor, thrombopoietin receptor (Mpl), IL-3 and granulocyte-colonystimulating factor receptors, are expressed differently during different hematopoietic cell differentiation. MC-specific receptor expression might exert the activation of JAK2V617 at a degree that differentially regulates MC proliferation and differentiation from CD34 þ cells. Recently, several JAK2 inhibitors have been reported to suppress the proliferation and/or induce the apoptosis of JAK2V617F þ cells. 38, [52] [53] [54] [55] In this study, we showed that erlotinib, a JAK2 inhibitor, effectively suppressed both the number and the size of MC colonies formed by JAK2V617F þ CD34 þ cells, while having moderate inhibitory effect on normal CD34 þ cells. These data show that MC progenitor cells are one of the cellular targets of JAK2 inhibitors.
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